NEW YORK, Jan. 5 (GenomeWeb News) - UBS today upgraded Cepheid's stock to 'Buy' from 'Neutral' claiming changes in the company's valuation make the stock more attractive.
Registering provides access to this and other free content.
Already have an account?Login Now.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.